Abstract
Introduction
Most health systems are attempting to improve patient safety [1, 2] , and medication errors are considered an important cause of avoidable morbidity and mortality [3, 4] . Adverse events in England may be responsible for 850,000 inpatient episodes, costing £2 billion in bed-days, and increased mortality [3, 5] . In NHS England, the recent White Paper, Equity and Excellence: Liberating the NHS, refers specifically to strategies to improve patient safety, including prescribing [6] .
Strategies to change prescribing behaviour are generally costly, with little evidence of cost effectiveness [7] [8] [9] . Furthermore, prescribing behaviour may not change as anticipated, and/or the clinical and resulting economic effects of most errors may be minor [10] . There have been few attempts to examine medical errors and adverse events from an economic perspective, far less to examine the cost effectiveness of interventions to reduce errors [11] . In a financially constrained healthcare environment, it is essential to be clearer about the true economic impact of medication error reduction. Systematic reviews demonstrate the high incidence of prescription errors in primary care, the errors causing most harm and where these errors occur in the medicines use process [12, 13] . There is little evidence that describes the clinical and economic impact of medication error reduction [1] . Studies reporting interventions to reduce errors may provide information around costs of the intervention or effects on prescribing budgets [14] , but not evidence around the effect of the intervention on patient outcome or costs.
Our cluster randomised controlled trial (RCT) demonstrated that a pharmacist-led information technology-based intervention (PINCER) reduced medication errors in general practices by 12.7 errors per practice at a cost per error avoided of £66 in year 2010 values (£79 in year 2012 values) [15] . This economic analysis only included PIN-CER intervention costs. Not knowing the impact of the intervention on patient health and NHS costs is an important limitation as the current UK evaluative framework requires a cost per QALY to compare the value for money of different healthcare interventions. Therefore, the aim of the economic analysis in this paper differs from our earlier preliminary analysis in that patient outcomes and healthcare costs incurred are estimated, rather than relying on the intermediate process indicator of errors.
Methods

Study Design, Comparators and Outcomes
Following published economic evaluation reporting criteria [16] , we compared the costs and patient outcomes of the PINCER intervention with simple feedback in reducing rates of six clinically important medication errors in 72 English general practices. Simple feedback to practices comprised information from their computer systems on patients at risk of medication error and educational material on each error. The PINCER intervention involved-in addition to simple feedback-a pharmacist working within practices for a 12-week period to correct existing errors and put in place measures to prevent future problems. Data were extracted at baseline and at 6 and 12 months postintervention. Primary [NSAIDs, b-blockers (b-adrenoceptor antagonists), ACE inhibitors (ACEIs)] and secondary (methotrexate, lithium, amiodarone) outcome measures were chosen as errors considered important in terms of overall burden and severity of iatrogenic harm in primary care [17] [18] [19] , and those detectable from general practice computer systems (Table 1) . Rationale for the choice of each measure is given in the trial protocol [20] . The PIN-CER trial sample size was determined according to the primary outcome measures at 6 months. Full details of the trial methods, results and initial economic analysis are available in the Electronic Supplementary Material and further detail is available elsewhere [15, 21] .
The cost per extra QALY generated was determined. We took the perspective of the funder (NHS England) in terms of direct costs of providing the intervention and managing the consequences of errors. This analysis combined the results from the PINCER trial with literaturederived error-specific projected harm to generate estimates of patient outcomes and NHS costs (Fig. 1 ).
Intervention Costs
The costs associated with simple feedback arose from researchers visiting practices at set time periods to generate error reports, reflecting the equivalent resource that would be consumed in practices to generate these reports. The PINCER intervention comprised these costs, plus pharmacist training sessions, facilitated meetings, monthly meetings, practice feedback meetings and time spent in each practice outside meetings following up errors [15, 20] .
Three reports were run in each practice (at baseline and at 6 and 12 months' follow-up), costing £98.41 per practice at 6 months' follow-up, and £147.62 per practice at 12 months' follow-up. In total, report generation cost £3,542.77 and £5,314.16 for 36 simple feedback and 36 PINCER intervention practices at 6 and 12 months, respectively. The PINCER arm also generated £10,529.26 training, £109.07 preparation, £7,395.42 facilitated meeting, £2,116.08 monthly meeting, £842.19 practice meeting and £15,519.67 error management costs. The components were summed together to give the total mean cost per practice in each arm (Table 2) . Further detail on methods is in the Electronic Supplementary Material.
Clinical and Economic Impact of Errors
PINCER reduced error rates across multiple disease areas. Most economic analyses operate within one therapeutic area. To generate costs and QALYs for PINCER we used a novel approach where economic models were developed for each error.
We modelled the effect of the observed error reductions at 6 months on patient outcomes and NHS costs, reflecting the timeframe for the primary outcomes. The outcomes described in Table 1 were included, requiring development of six models describing the consequences of the errors (see Fig. 1 ). Markov models were designed and populated with probabilistic data. Each model had a 3-month cycle length with half-cycle correction, a 5-year time horizon, 2012 cost year, and the UK Treasury-recommended 3.5 % discount rate for costs and outcomes [22] . Summaries of model development are available in the Electronic Supplementary Material. A full account is available elsewhere [23] .
Sources of Data
In the NSAIDs model, with some drugs in this class being quite recently licensed and existing economic models focusing on relative gastrointestinal safety, we were able to build on existing search strategies and access relevant evidence for probabilities, costs and utilities, and use published economic models to optimise design. In the other five models, the drugs involved are established therapies available as generics with few or no economic models having been built for regulatory purposes or to investigate safety, so the quantity and quality of evidence was much older and poorer, requiring more extensive searching, consultation with clinical experts and tentative model design.
Literature Searches
The literature search was conducted through MEDLINE, EMBASE and Web of Science search terms that were specific to the errors (see the Electronic Supplementary Material). References in English and limited to humans were included. Databases were searched to the end of 2010. In the NSAIDs model we built on existing search strategies and a published systematic review and economic evaluation [24, 25] . No existing search strategies were available for other models and, despite including broad inclusion criteria, searches yielded low quantities of evidence.
Comprehensive hand searches of the literature were also employed but in some instances only poor-quality published evidence was identified.
Individual Model Design
Model design was informed by published models where possible. In NSAIDs, there are many models that address gastrointestinal toxicity [25, 26] . For the b-blocker model, we adapted published models of asthma management [27, 28] . For outcomes where no published models exist, we had to develop new models with advice from clinical experts (see Acknowledgments). This included a model examining the effect of lack of monitoring of ACEIs on potassium levels or renal function or the effect on patient outcomes; a model examining the effect of lack of monitoring in methotrexate; a lithium model incorporating lithium intoxication where the literature is complex and contradictory [29] [30] [31] ; and a model examining the effect of lack of amiodarone monitoring, where there is lack of consensus around management [32] .
Transition Probabilities
Data came preferentially from up-to-date UK sources that reflected the PINCER trial patient characteristics. The amount, quality and relevance of evidence varied greatly for the different models. We accessed data from relevant RCTs and meta-analyses for the NSAIDs model to provide relatively reliable estimates of probabilities in the appropriate patient group. In other models, such as the b-blocker and ACEI models, there was very little relevant published evidence, despite very inclusive search strategies, requiring discussion with clinical experts. Definitions for outcomes varied in the literature, such as hyperkalaemia (ACEI model) [33, 34] and relapse in bipolar disorder (lithium model) [35, 36] .
Identifying the Effect of the Error on Outcomes
Identifying the effect of errors on outcomes was straightforward in the NSAIDs model, as risk reductions were documented for patients who were prescribed an NSAID with a proton pump inhibitor versus patients with NSAIDs alone in the study by Pettit et al. [37] . Observational data then provided relevant, detailed and up-to-date information on death rates associated with hospitalisation for a gastric bleed in the UK [24] . However, in other models little evidence was found around the effect of the error, requiring the use of multiple sources of data (methotrexate model) or expert opinion (ACEI model). In the ACEI model, probabilities were available for developing acute renal failure (ARF) in the presence of [38] and absence of [39, 40] monitoring and death due to ARF [41] . However, the probability of developing hyperkalaemia as a result of ACEIs was not documented and, after discussion with clinical experts, we assumed a similar rate as for development of ARF in the absence of monitoring. In the amiodarone model, no studies reported the effects of monitoring thyroid function on patient outcomes. If patients are monitored, it is assumed that they will have a lower probability of staying in the untreated states with the associated increased risk of morbidity and mortality. If a patient is being monitored regularly, thyrotoxicity will be picked up and treated within one cycle. The probability of surgical management via thyroidectomy in amiodaroneinduced thyrotoxicity is 0.081 [42] . It was assumed that the probability will be higher than zero as patients may be picked up by chance, at a rate of 10 % of the rate in the monitored group.
Health Status
In the NSAIDs model, directly relevant health status valuation was available for each of the health states [43] and this was also available in the lithium model for nondepressive health states [44] . In other models (b-blockers, ACEIs, lithium), we had to approximate relevant health state valuations from the literature, e.g. by using data from patients with major depression to approximate for bipolar patients in a depressive relapse [45] . In the methotrexate model, we had to estimate health states for bone marrow suppression due to the lack of available published estimates.
Resource Use and Unit Costs
Resource use data came preferentially from up-to-date UK sources of observation of clinical practice, with disaggregated resource use data, to allow attachment of current unit prices. If possible, individual patient data were used, with associated measures of mean and variation. If these were not available, point estimates were used, with carefully specified deterministic ranges, and standard methods for allocating distributions to these data were used. In the NSAIDs model, previous work by Elliott and colleagues [25] provided disaggregated resource use data for each health state. In the b-blocker and lithium models, we utilised published data [28, 46] . However, in other models, such as the ACEI and methotrexate model, there was very little published evidence, requiring reliance on clinical experts. The probability, cost and utility data were assigned beta, gamma and beta distributions, respectively, and are summarised in Tables 3 and 4 . Costs are given in year 2012 values.
Incremental Analysis
Each model was populated with probability, cost and health status data. This allowed the generation of the outcomes and costs in a cohort with the error present, and in a cohort with the error absent. PINCER is a practice-level intervention with an associated practice-level effect and intervention costs. The error rates are reported at practice level but the Markov models generate costs and outcomes at patient level. Therefore, we needed to estimate, per practice, the difference in costs and outcomes generated for the PINCER and simple feedback arms. For the composite economic model, we assumed a practice with the characteristics of the mean in the PINCER trial practices. In the 36 practices in the control arm, at baseline, there were 28,769 patients in total at risk of one of the six errors [NSAIDs: 1,970 (7 %); bblockers: 20,634 (71 %); ACEIs: 4,722 (16 %); methotrexate: 966 (4 %); lithium: 224 (1 %); amiodarone: 253 (1 %)]. This means that, in one typical practice in the PINCER trial, 799 patients were at risk of one of the six errors (NSAIDs: 55; b-blockers: 573; ACEIs: 131; methotrexate: 27; lithium: 6; amiodarone: 7). Therefore, in the composite economic model we estimated the difference in error rate between PINCER and simple feedback interventions at 6 months' follow-up for this practice population. The incidence rate for each error at 6 months' followup in the PINCER and simple feedback arms were combined with the appropriate error-specific model. Using the error-specific models, we generated the difference in patient outcome and costs between PINCER and simple feedback for each error for this practice population. Probabilistic estimates of costs and outcomes were derived, the analysis generating 5,000 iterations, using Monte-Carlo simulation for each error. The model assumes that no new patients enter the practice during the 5-year period.
This allowed us to generate the incremental impact of the PINCER intervention costs and outcomes for each error group in the practice population. The incremental costs and outcomes associated with each error were incorporated additively into the economic model. This allowed derivation of the total incremental impact of the PINCER intervention costs and outcomes for all six errors for one practice. At this point, the practice-level PINCER intervention or simple feedback costs were combined with these data.
Deterministic and probabilistic incremental economic analyses were carried out using these cost and outcome data. The incremental cost per extra QALY generated by PINCER over simple feedback was calculated using the following equation:
It is not possible to generate 95 % confidence intervals around incremental cost-effectiveness ratios (ICERs) because the ratio of two distributions does not necessarily have a finite mean or, therefore, a finite variance [47] . Therefore, generation of a bootstrap estimate of the ICER sampling distribution to identify the magnitude of uncertainty around the ICERs is required. Bootstrapping with replacement was employed, utilising Microsoft Ò Excel Ò , using a minimum of 5,000 iterations to obtain 2.5 and 97.5 % percentiles of the ICER distribution.
Negative ICERs are difficult to interpret and often arise when one of the interventions is either 'dominant' (more effective, less costly) or 'dominated' (less effective, more costly). It is not possible to tell this from the ICER itself. Therefore, it is clearer to state that the intervention is dominant or dominated, rather than to present ICERs. We report the proportion of ICER estimates in each of the four quadrants of the cost-effectiveness plane. We present mean ICERs for all results, indicating for negative ICERs whether the intervention is dominant or dominated.
Cost-effectiveness acceptability curves [48] were constructed to express the probability that PINCER is cost effective as a function of the decision maker's ceiling costeffectiveness ratio (k) for base-case, sensitivity and scenario analyses [49] .
The incremental net monetary benefit (INB) was estimated using the following formula: Table 3 continued a Net of other probabilities at this node b Probabilities in non-error model derived from error probabilities multiplied by risk reduction from Pettit et al. [37] c Probabilities are calculated as the probability of no GI adverse event to the respective destination state multiplied by relative risk derived from Pettitt et al. [37] ACEI ACE inhibitor, AIH amiodarone-induced hypothyroidism, AIT amiodarone-induced thyrotoxicity, ARF acute renal failure, BMS bone marrow suppression, GI gastrointestinal, PPI proton pump inhibitor where it was calculated for k ranging from £0 to £160,000.
Sensitivity and Scenario Analysis
The errors included in the intervention were varied in the following scenario analyses: each error separately; three PINCER primary outcome errors only; prescribing errors only; monitoring errors only; dominated errors removed; and only the two most cost-effective errors included. The costs associated with the PINCER intervention were varied. The practice size affects the intervention cost and some costs are practice level (i.e. costs per patient would be lower for larger practices), so this was varied. Table 5 summarises the 5-year costs and outcomes derived from each error-specific model. Table 6 summarises the inputs, QALYs gained and costs for the deterministic incremental analysis of the PINCER intervention and simple feedback practices. The PINCER intervention generated 0.81 extra QALYs per practice, compared with simple feedback at £2,679 less per practice. Therefore, the PINCER intervention 'dominated' simple feedback.
Results
In the probabilistic analysis, mean [standard error (SE)] QALYs generated per simple feedback and PIN-CER practice were 3.141 (0.003) and 3.142 (0.003), respectively. Costs (SE) incurred per simple feedback and PINCER practice were £853 (3.05) and £844 (3.07), respectively. The PINCER intervention generated 0.001 extra QALYs per practice compared with simple feedback, at £4.20 less per practice. Despite this extremely small set of differences in costs and outcomes, the PINCER intervention dominated simple feedback with a mean ICER of -£3,936 (SE £2,970) ( Table 7 ; Fig. 2) .
At the National Institute of Health and Care Excellence (NICE) unofficial threshold, ceiling willingness-topay for a QALY of £20,000, PINCER reached a 59 % probability of being cost effective. The probability of PINCER being cost effective did not increase beyond this percentage (see Fig. 3 ). The net benefit statistic, applying [43] , assuming an SE of 2 % around these numbers and applying a gamma distribution a k = £20,000, generated a mean of £16 (standard deviation £121; median £22; 2.5th percentile -£218; 97.5th percentile £242).
If the PINCER intervention targeted one of the errors only, the mean (SE) costs per QALY generated were as follows: NSAIDs: -£22,055 (£108), dominant; b- Table 6 Summary of inputs and incremental cost-effectiveness ratios generated for deterministic incremental analysis of PINCER intervention versus simple feedback blockers: £2,610 (£3,691); ACEI: -£7,207 (£5,685), dominated; methotrexate: £4,960 (£8,760); lithium: -£27,577 (£21,995), dominant; and amiodarone: £515 (£16). As ACEI was dominated, we re-ran the model without it. This increased the probability of cost effectiveness at k = £20,000 to 65 %. Including only the two most robust models (NSAIDs and amiodarone) increased the probability of cost effectiveness at k = £20,000 to 100 %. Other scenario analyses are reported in Table 7 . Varying the cost of the intervention or the practice size had a negligible effect on results (Table 7) . Fig. 2 Cost-effectiveness plane for PINCER intervention versus simple feedback Fig. 3 Cost effectiveness acceptability curve for PINCER intervention versus simple feedback. This graph demonstrates the probability of cost effectiveness at a range of decision-maker ceiling willingness-to-pay values for the PINCER intervention overall, and also when only one error is considered at a time. ACEI ACE inhibitor 4 Discussion PINCER produced a marginal health gain at a slightly reduced overall cost. The results suggest that PINCER increased health gain at a cost per QALY well below most accepted thresholds for technology implementation, usually about £20,000 to £30,000 in the UK [50] . However, results are uncertain due to the poor quality of data to inform the effect of avoiding errors. The wide range around the point estimates of cost effectiveness reflects the uncertainty in some of the individual error models. This uncertainty translates into the probability of cost effectiveness never reaching 90 % and the net benefit statistic, whilst having a positive mean, having a range that incorporates both positive and negative values, suggesting the possibility of both net benefit and net cost.
Targeting NSAID prescribing and amiodarone monitoring errors were the most cost-effective activities. Targeting errors with evidence of effects on patient outcomes will increase the cost effectiveness of the intervention. In contrast, varying the cost of the intervention or the practice size had a negligible effect on results.
Investigation of how each outcome contributes to the cost effectiveness of PINCER demonstrates that correcting errors in NSAID prescribing alone and amiodarone monitoring alone would generate 95 % probabilities of PINCER being cost effective at £10,000 and £0 per QALY gained, respectively. However, correcting errors in b-blocker prescribing and ACEI, diuretic, lithium and methotrexate monitoring may not be cost effective within current thresholds for cost effectiveness. Because NSAID prescribing and amiodarone monitoring accounted for only 8 % of the overall errors corrected, the effects are swamped by the other errors. The quality of the evidence for the clinical and economic impact of NSAID prescribing and amiodarone monitoring errors was better than that available for other errors. The errors with a poor level of evidence showed more uncertainty around their clinical and economic impact within the PINCER intervention.
Strengths and Limitations
This analysis has included the costs or outcomes that may have been incurred as a result of the errors, giving an estimate of clinical and economic impact of the intervention. We believe that moving beyond the use of process indicators such as error rates and combining multiple errorspecific models determining the full economic impact of error-reducing interventions is an important development.
The key limitation of this analysis is the paucity of data upon which to base the estimates of the economic impact of the individual errors. This economic model has been in development since 2008 and was submitted to the funder in 2012. Updating the searches from 2008 to 2010 uncovered no new evidence to populate models as there is very little work going on in this area. One of the limitations of this approach is that the building of each model and incorporation into the composite model is resource intensive. Further work is needed to quantify the actual clinical and economic effect of prescribing and monitoring errors, to provide better data to populate the models. For example, apart from the NSAIDs model, we were not able to incorporate how long a patient might have been exposed to a potential drug interaction or lack of monitoring due to the paucity of data available. Analysis of clinical databases might help us to estimate more accurately the costs and outcomes of errors.
The costs of the simple feedback and PINCER intervention arms reflect one way in which the interventions would be implemented in practice [15] . Differing practice characteristics and methods of service provision may affect costs, although in the cluster RCT there was no evidence of statistically significant interactions between treatment arm and either practice size or practice deprivation for any of the primary outcome measures or intervention costs [21] . This economic analysis did not include any practice costs associated with time spent dealing with errors. It is not clear which arm this omission would favour as practices in the intervention arm spend time with the PINCER pharmacist, but simple feedback practices would have to sort out errors themselves, rather than the pharmacist doing it. However, this means that the costs presented are an underestimate of the real cost to the practice. Ongoing pharmacist support might be needed to maintain (or further reduce) error levels in the intervention group, which would increase intervention costs. We have not considered the costs of implementing this intervention more widely, which would further increase costs.
PINCER was compared with simple feedback rather than usual care because it would have meant identifying patients at risk but not making these known to the practice, which was considered unethical. It may be reasonable to suppose that simple feedback is more effective than usual care. However, this is not the case in another similar study [51] and in the PINCER trial any improvements in the simple feedback error rate were attributed to secular changes [21] .
This analysis may have underestimated the true impact of PINCER because not all benefits from a pharmacist intervention may be captured in our analyses. For example, there may have been a reduction in other errors, as the PINCER practice-level approach process of examining causes of errors within a practice may lead prescribers to question other aspects of their prescribing and monitoring.
Some benefits that may be associated with the reduction of medication errors might not contribute to QALYs gained, but may 'go beyond health' [52] and generate other 'outcomes' such as increased patient trust in the NHS associated with lower error rates, regardless of their clinical significance.
Implications for Policy and Practice
To facilitate formal commissioning decisions under current NHS frameworks, we have attempted to determine the expected cost per QALY gained through the implementation of PINCER. To our knowledge, this is the first attempt to determine the true economic impact of reducing medication errors through the implementation of a complex intervention.
In summary, the results of this study suggest that targeting some errors could prove more cost effective than targeting all errors, and could be considered by policy makers. More research is required to assess costs of wider implementation and to better characterise the impact of individual errors.
Conclusions
Despite a significant reduction in errors, the findings of this economic analysis suggest that the PINCER intervention produced marginal health gain at slightly reduced overall cost. We have been unable to quantify with any level of certainty the impact of the PINCER intervention due to the poor quality of data to inform the effect of avoiding errors. Targeting NSAID prescribing and amiodarone monitoring errors were the most cost-effective activities. The wide range around this ICER reflects the uncertainty around the real effect of some errors. Targeting errors with evidence of effects on patient outcomes will increase the cost effectiveness of the intervention. More evidence is critical to support the selection of evidence-based errors for this type of intervention.
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